VRDNViridian Therapeutics, Inc. Common Stock

CSNasdaq (XNAS)·USD

Identity

Security key: 23452
Ticker: VRDN
Type: CS — Common Stock
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 2014-06-18
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: VRDN

Detail

Enriched 2026-08-14 20:47

Market cap: $2,592,127,114.72
Shares outstanding (class): 113,292,269
Shares outstanding (weighted): 113,292,269
SIC: 2834 PHARMACEUTICAL PREPARATIONS
Employees: 252
Location: WALTHAM, MA
Homepage: https://www.viridiantherapeutics.com
Description: Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.

Market cap and share counts drift.

Funds holding this security

132 funds · 134 positions · $344.18M reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS	VTI	$60.98M	0.00%	3,117,340 NS	FIGI
State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST	XBI	$52.17M	0.70%	2,667,007 NS	FIGI
iShares Russell 2000 ETF iShares Trust	IWM	$38.92M	0.05%	1,989,546 NS	FIGI
T. Rowe Price New Horizons Fund, Inc. T. ROWE PRICE NEW HORIZONS FUND, INC.	—	$20.50M	0.16%	1,047,958 NS	FIGI
VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS	VXF	$18.54M	0.02%	947,805 NS	FIGI
T. Rowe Price Integrated U.S. Small-Cap Growth … T. ROWE PRICE INTEGRATED EQUITY FUNDS, INC.	—	$13.31M	0.16%	680,599 NS	FIGI
Fidelity U.S. Equity Central Fund Fidelity Central Investment Portfolios LLC	—	$13.30M	0.07%	680,000 NS	FIGI
iShares Russell 2000 Growth ETF iShares Trust	IWO	$10.30M	0.08%	526,755 NS	FIGI
Loomis Sayles Small Cap Growth Fund LOOMIS SAYLES FUNDS II	—	$10.15M	0.53%	518,716 NS	FIGI
VIP Health Care Portfolio Variable Insurance Products Fund IV	—	$10.07M	1.00%	515,000 NS	FIGI
T. Rowe Price Health Sciences Fund, Inc. T. ROWE PRICE HEALTH SCIENCES FUND, INC.	—	$6.73M	0.06%	343,846 NS	FIGI
VANGUARD STRATEGIC EQUITY FUND VANGUARD HORIZON FUNDS	—	$5.27M	0.05%	269,533 NS	FIGI
iShares Micro-Cap ETF iShares Trust	IWC	$4.01M	0.33%	205,083 NS	FIGI
BlackRock Health Sciences Term Trust —	—	$3.39M	0.33%	173,120 NS	FIGI
VANGUARD STRATEGIC SMALL-CAP EQUITY FUND VANGUARD HORIZON FUNDS	—	$2.89M	0.12%	147,866 NS	FIGI

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

Funds holding this security

Identifiers

master.security_identifier

TICKERVRDN
FIGI_COMPOSITEBBG002H242Z5
FIGI_SHARE_CLASSBBG002H24301
CIK0001590750
ISINUS92790C1045
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Pharmaceuticals
Source: LLMunreviewed
Self-reported confidence: 0.9
Model: deepseek
Rationale: Viridian Therapeutics is a biopharmaceutical company developing treatments, classified under pharmaceutical preparations per SIC.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.